Analysis of the clinical characteristics of tigecycline-induced hypofibrinogenemia

References

• Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother. 1999;43(4):738–744.
   PubMed Web of Science ®Google Scholar
• Kaewpoowat Q, Ostrosky-Zeichner L. Tigecycline: a critical safety review. Expert Opin Drug Saf. 2015;14(2):335–342.
   PubMed Web of Science ®Google Scholar
• Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006;26(8):1099–1110.
   PubMed Web of Science ®Google Scholar
• Doan TL, Fung HB, Mehta D, et al. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther. 2006;28(8):1079–1106.
   PubMed Web of Science ®Google Scholar
• Akhter S, Krishnan P, Kaul P. Tigecycline-associated acute pancreatitis. Am J Ther. 2018;25(6):e749–e750.
   PubMed Web of Science ®Google Scholar
• Cui N, Cai H, Li Z, et al. Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm. 2019;41(6):1408–1413.
   PubMed Web of Science ®Google Scholar
• Ray A, Sharma S, Atal S, et al. Tigecycline-induced severe hypoglycemia in a Non-Diabetic individual: a case report and brief review of tigecycline-induced severe hypoglycemia. Am J Case Rep. 2020;21:e924556.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhou S, Zhou J. Tigecycline treatment causes a decrease in fibrinogen levels. Antimicrob Agents Chemother. 2015;59(3):1650–1655.
   PubMed Web of Science ®Google Scholar
• Hu J, Xiao YH, Zheng Y, et al. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients. Eur J Clin Pharmacol. 2020;76(7):913–922.
   PubMed Web of Science ®Google Scholar
• Routsi C, Kokkoris S, Douka E, et al. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. Int J Antimicrob Agents. 2015;45(1):90–93.
   PubMed Web of Science ®Google Scholar
• Balfousias T, Apostolopoulos AP, Angelis S, et al. Spontaneous knee hemarthrosis due to hypofibrinogenemia following tigecycline treatment for periprosthetic joint infection. Cureus. 2019; Oct 1011(10):e5883.
   PubMed Web of Science ®Google Scholar
• Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol. 1992;29(3):177–188.
   PubMedGoogle Scholar
• Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. Blood. 2015;125(9):1387–1393.
   PubMed Web of Science ®Google Scholar
• Martini WZ. Fibrinogen metabolic responses to trauma. Scand J Trauma Resusc Emerg Med. 2009;17:2. 13
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Primary hyperfibrinolysis: facts and fancies. Thromb Res. 2018;166:71–75.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhao P, Dong L, et al. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia. Medicine (Baltimore). 2017;96(49):e9124.
   PubMed Web of Science ®Google Scholar
• Noah Scheinfeld. Tigecycline: a review of a new glycylcycline antibiotic. J Dermatolog Treat. 2005;16:207–212.
   PubMed Web of Science ®Google Scholar
• Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56(3):470–480.
   PubMed Web of Science ®Google Scholar
• Peterson LR. A review of tigecycline: the first glycylcyclines. Int J Antimicrob Agents. 2008;32:S215–S222.
   PubMed Web of Science ®Google Scholar
• Brink AJ, Bizos D, Boffard KD, et al. Guideline: appropriate use of tigecycline. S Afr Med J. 2010;100(6 Pt 2):388–394.
   PubMed Web of Science ®Google Scholar
• Cunha BA, Baron J, Cunha CB. Once daily high dose tigecycline - pharmacokinetic/pharmacodynamic based dosing for optimal clinical effectiveness: dosing matters, revisited. Expert Rev Anti Infect Ther. 2017;15(3):257–267.
   PubMed Web of Science ®Google Scholar
• Campany-Herrero D, Larrosa-Garcia M, Lalueza-Broto P, et al. Tigecycline-associated hypofibrinogenemia in a real-world setting. Int J Clin Pharm. 2020;42(4):1184–1189.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang J, Liu H, et al. Risk factors for tigecycline-induced hypofibrinogenaemia. J Clin Pharm Ther. 2020;45(6):1434–1441.
   PubMed Web of Science ®Google Scholar
• Wu PC, Wu CC. Tigecycline-associated hypofibrinogenemia: a case report and review of the literature. ID Cases. 2018;11:56–57.
   Google Scholar
• Sabanis N, Paschou E, Gavriilaki E, et al. Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder. Infect Dis (Lond). 2015;47(10):743–746.
   PubMed Web of Science ®Google Scholar
• Korth-Bradley JM, Troy SM, Matschke K, et al. Tigecycline pharmacokinetics in subjects with various degrees of renal function. J Clin Pharmacol. 2012;52(9):1379–1387.
   PubMed Web of Science ®Google Scholar
• Vasse M, Paysant I, Soria J, et al. Down-regulation of fibrinogen biosynthesis by IL-4, IL-10 and IL-13. Br J Haematol. 1996;93(4):955–961.
   PubMed Web of Science ®Google Scholar
• Saliba R, Paasch L, El Solh A. Tigecycline attenuates staphylococcal super antigen induced T-cell proliferation and production of cytokines and chemokines. Immunopharmacol Immunotoxicol. 2009;31(4):583–588.
   PubMed Web of Science ®Google Scholar
• Fish RJ, Neerman-Arbez M. Fibrinogen gene regulation. Thromb Haemost. 2012;108(3):419–426.
   PubMed Web of Science ®Google Scholar
• Pieringer H, Schmekal B, Biesenbach G, et al. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Ann Hematol. 2010;89(10):1063–1064.
   PubMed Web of Science ®Google Scholar
• Rossitto G, Piano S, Rosi S, et al. Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis. Eur J Gastroenterol Hepatol. 2014;26(6):681–684.
   PubMed Web of Science ®Google Scholar
• Giryes S, Azzam ZS, Ismael-Badarneh R, et al. Severe coagulation disorder and thrombocytopenia associated with tigecycline - case report and review of literature. Curr Drug Saf. 2017;12(1):7–9.
   PubMed Web of Science ®Google Scholar